Premium
Intravascular ultrasound analysis of small vessel lesions treated with the sparrow coronary stent system: Results of the CARE II trial
Author(s) -
Kume Teruyoshi,
Waseda Katsuhisa,
Koo BonKwon,
Yock Paul G.,
Botelho Roberto,
Verheye Stefan,
Whitbourn Robert,
Meredith Ian,
Worthley Stephen,
Hai Koh Tian,
Honda Yasuhiro,
Abizaid Alexandre,
Fitzgerald Peter J.
Publication year - 2013
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.24867
Subject(s) - sparrow , medicine , stent , intravascular ultrasound , bare metal stent , surgery , radiology , drug eluting stent , restenosis , ecology , biology
Objectives The aim of this study was to evaluate the Sparrow sirolimus‐eluting stent (Sparrow‐SES) against the Sparrow bare‐metal stent (Sparrow‐BMS) and conventional balloon‐expandable bare‐metal stent (BMS: Driver/Micro‐Driver ® stent, Medtronic Vascular, Santa Rosa, CA). Background The Sparrow ® stent (Biosensors International, Singapore) consists of a guide wire‐based, self‐expandable, ultra‐thin nitinol stent. The performance of this device with sirolimus in a fully biodegradable polymer has not been determined. Methods A total of 74 patients were included in this intravascular ultrasound (IVUS) sub‐study of the CARE II trial, which was a prospective, randomized, multicenter trial in the treatment of single de novo native coronary artery lesions in vessels ranging from 2.0 mm to 2.75 mm in diameter (Sparrow‐SES: n = 31, Sparrow‐BMS: n = 22, BMS: n = 21). Results Stent volume index (VI) was significantly increased 8‐month later in Sparrow‐SES and Sparrow‐BMS, but not in BMS (4.0±1.0 to 4.6±1.0 mm 3 /mm, p<0.0001, 4.0±0.6 to 4.4±0.8 mm 3 /mm, p<0.05, and 5.2±1.0 to 5.1±0.9 mm 3 /mm, p=0.421, respectively). % neointimal obstruction in Sparrow‐SES was significantly smaller than those in Sparrow‐BMS and BMS at follow‐up (17.6±9.4 vs. 36.2±13.8 and 39.9±11.1%, p<0.001). Sparrow‐SES showed a mean 15% stent expansion and good suppression of neointimal proliferation, resulting in a significantly lower percentage of change in lumen VI during follow‐up period (Sparrow‐SES: −6.2±16.2%, Sparrow‐BMS: −30.4±11.6%, BMS: −40.4±10.0%, p<0.001). Conclusions The self‐expanding Sparrow‐SES demonstrated chronic stent expansion, good suppression of neointimal proliferation and resulted in a more preserved lumen in stented small vessels compared with the Sparrow‐BMS and conventional balloon expandable BMS. © 2013 Wiley Periodicals, Inc.